News
New Weight Loss Pill From Eli Lilly Shows Promise in Early Study
FRIDAY, Aug. 8, 2025 (HealthDay News) — A new weight loss pill made by Eli Lilly helped people lose a significant amount of weight in a recent study. Taken at the highest dose, orforglipron helped patients lose an average 27.3 pounds, or 12.4% of their body weight, over 72 weeks.
In the wake of this sell-off, a critical question arises about whether LLY stock represents a buying opportunity.
Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...
2hon MSN
Eli Lilly Stock Is On Track for Its Worst Performance Since 2008. Should Investors Be Worried?
The stock is struggling badly, and if things don't improve in short order, Eli Lilly will be on track for its worst ...
Pharmaceutical Technology on MSN22h
Mounjaro and Zepbound fuel strong Q2 growth for Eli Lilly
Eli Lilly reported $15.56bn in revenue, driven by its weight loss and diabetes drugs, intensifying pressure on rival Novo ...
Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...
In May, it announced it would acquire SiteOne Therapeutics, a drugmaker with a promising investigational medicine for pain.
The FDA says shortages of GLP-1s are over, but many patients are still getting what are essentially copied medications.
Medindia on MSN1d
Zepbound Approved as First Drug for Sleep Apnea in Obese Adults
Zepbound functions by targeting hormone receptors related to appetite regulation, specifically glucagon-like peptide-1 and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback